2023 World Conference on Lung Cancer (Posters)-P2.11. Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

P2.11. Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION - PDF(Slides)

Back to course

Pdf Summary

The long-term follow-up results from the VISION trial were presented, focusing on Asian patients with non-small cell lung cancer (NSCLC) who had MET exon 14 skipping mutations. Tepotinib, a highly selective MET tyrosine kinase inhibitor (TKI), demonstrated durable clinical activity in this patient population. The overall response rate (ORR) was 56.6%, with a median progression-free survival (PFS) of 13.8 months and median overall survival (OS) of 25.5 months. In patients who received tepotinib as a first-line treatment, the ORR was 64.0%, with a median PFS of 16.5 months and median OS of 32.7 months. The safety profile of tepotinib was manageable, with the majority of adverse events being grade 1 or 2.<br /><br />Health-related quality of life (HRQoL) data showed that the scores remained stable during treatment in Asian patients. The study included the largest population of Asian patients with MET exon 14 skipping NSCLC in a MET TKI trial, and the efficacy outcomes in this subgroup were comparable to those seen in the overall population.<br /><br />These results support the use of tepotinib as a treatment option for Asian patients with MET exon 14 skipping NSCLC, both as a first-line treatment and in later lines of therapy. Tepotinib has been incorporated into clinical practice guidelines, including the Asian Thoracic Oncology Research Group (ATORG) Expert Consensus, for the treatment of these patients. Overall, tepotinib demonstrated durable clinical activity and a manageable safety profile in Asian patients with MET exon 14 skipping NSCLC.

Asset Subtitle

Myung-Ju Ahn

Meta Tag

Speaker Myung-Ju Ahn

Topic Metastatic NSCLC: Targeted Therapy - KRAS/MET

Keywords

VISION trial

Asian patients

NSCLC

MET exon 14 skipping mutations

tepotinib

clinical activity

overall response rate

progression-free survival

overall survival

first-line treatment